炎炎夏日，被蚊虫叮咬是常事，涂抹一点清凉油，便能迅速止痒消肿；咽喉肿痛时，含服一片西瓜霜含 片，冰凉的感觉会让嗓子舒服很多。在这些我们熟知的药物中，都有一个神秘的"功臣"——冰片。 冰片被誉为中药领域里的"清凉使者"，不仅能开窍醒神，还能消肿止痛，是传统中药里的珍贵之品。 从"龙脑香"到现代冰片 打开家庭药箱，含冰片的药品随处可见：缓解咽喉肿痛的西瓜霜含片、提神醒脑的风油精……这些药物 能清凉消肿止痛、快速起效，都离不开冰片的功劳。 在中成药领域，冰片更是"明星成分"：在安宫牛黄丸中，它能够开窍醒神，可用于中风昏迷患者的急 救；在复方丹参滴丸和速效救心丸中均含有冰片，可借助它来促进药物吸收，迅速缓解心绞痛症状；还 有一些外用药物如痔疮膏、滴眼液中也加入冰片，发挥清凉消肿止痛的功效。 但是，这并不意味着冰片就是能"包治百病"的神药。 警惕"万能药"陷阱 冰片的历史，最早可追溯到南北朝时期。当时东南亚的龙脑香树树脂传入中国，因其"状如云母，色如 冰雪"，古人称之为"神药"，将其命名为"龙脑"，也就是现在所说的冰片。当时，获取龙脑极其困难， 其产量也极低，因此只有贵族才能使用这味药材。 到了唐代，冰片更是受到了皇室 ...

证券研究报告·公司深度研究·中药Ⅱ 天士力（600535） 中药现代化领军企业，华润入主，厚积薄发 2025 年 06 月 22 日 买入（首次） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 8,674 | 8,498 | 8,994 | 9,606 | 10,189 | | 同比（%） | 0.42 | (2.03) | 5.83 | 6.81 | 6.06 | | 归母净利润（百万元） | 1,071.07 | 955.59 | 1,152.06 | 1,335.09 | 1,503.11 | | 同比（%） | 505.34 | (10.78) | 20.56 | 15.89 | 12.58 | | EPS-最新摊薄（元/股） | 0.72 | 0.64 | 0.77 | 0.89 | 1.01 | | P/E（现价&最新摊薄） | 21.62 | 24.23 | 20.10 | 17.34 | 15.41 | [T ...

Core Insights - The 10th Smart Pharmaceutical Academic Industry Conference was held in Tianjin, showcasing advancements in traditional Chinese medicine and smart manufacturing [1][3] - Tianshili Pharmaceutical Group played a significant role in the conference, presenting its strategic layout and technological breakthroughs in smart manufacturing [3][10] - The conference emphasized the importance of digital transformation in the pharmaceutical industry, with Tianshili leading initiatives to establish industry standards [3][10] Group 1: Conference Highlights - The conference gathered over 300 industry elites and top experts, including Academician Zhang Boli, to discuss the future of smart pharmaceuticals [1] - Tianshili's Chairman Zhou Hui and other executives presented reports on the company's advancements in digital quality systems and smart manufacturing technologies [3][5] - The event featured the launch of the "Pharmaceutical Industry Digital Action Tianjin Initiative," highlighting Tianshili's leadership in industry transformation [3][10] Group 2: Technological Innovations - Tianshili's digital quality system integrates blockchain traceability, AI process optimization, and smart equipment control, enhancing product quality consistency to international standards [5][12] - The company developed a fifth-generation high-speed jet granulator, addressing production challenges and significantly improving efficiency [7][8] - Tianshili's smart production line automates the entire process from raw material input to finished product packaging, showcasing its commitment to technological advancement [8][12] Group 3: Research and Development - Tianshili has established a comprehensive R&D model that integrates modern Chinese medicine, biopharmaceuticals, and precision medicine, leading to the launch of new products [12] - The company has completed three new drug registration applications and seven clinical research applications in the past year, with a pipeline of 98 products, including 33 innovative drugs [10][12] - Tianshili's commitment to digital transformation and R&D innovation positions it as a leader in modernizing the traditional Chinese medicine industry [12][13] Group 4: Future Outlook - The release of the Tianjin Initiative marks a new phase of collaborative innovation in the pharmaceutical industry's digital transformation [13] - Tianshili aims to empower the health of China through its "Digital Chinese Medicine + Innovative Chinese Medicine" strategy, emphasizing the necessity of digital transformation for the industry [13] - The company is poised to continue leading the modernization of traditional Chinese medicine through technological advancements and patient-centered approaches [13]

速效救心丸、硝酸甘油和复方丹参滴丸是我们耳熟能详的药物，也是心脏疾病患者常备的几种药物。这 些药物虽均能缓解心绞痛急性发作，但成分、作用机制和适用人群差异较大。当心绞痛突然发作时，到 底应该选择哪种药物是很多中老年患者的疑问。今天，药师带您来了解一下这三种"救命药"。 硝酸甘油 急性心绞痛的首选药 成分 川芎、冰片。 药理作用 扩张血管 适应症 用于预防和迅速缓解因冠状动脉疾病引起的心绞痛发作。 用法用量 在心绞痛急性发作时，应舌下或在口腔颊黏膜处含化一片。 禁忌 心肌梗死早期、严重贫血、颅内压升高患者、急性循环衰竭或休克患者禁用；正在服用枸橼酸西 地那非的患者禁用。 药师提示 硝酸甘油是急性心绞痛的首选药物，因其扩张血管效果较强，若患者血压较低，则不建议服 用。 《稳定性冠心病基层诊疗指南(2020年）》指出舌下含服或喷雾硝酸甘油可作为心绞痛急性发作时缓解 症状用药，也可在运动前数分钟预防使用。心绞痛急性发作时，可每5分钟重复一次，如果15分钟内给 药3片胸痛仍不缓解，或疼痛加剧，请立即拨打120急救。 硝酸甘油为舌下片，不可以咀嚼、压碎或吞服。吃药时最好取坐位。硝酸甘油约1-3分钟可起舒张血管 作用，服药 ...

Core Insights - The 2025 Wuzhen Health Conference recognized Tianshili (600535.SH) as a VIP strategic partner and awarded its products for innovation and popularity in the retail market [1] - The Chinese pharmaceutical retail market is projected to reach 501.9 billion yuan in 2024, driven by policy changes and demographic shifts [3] - Tianshili focuses on integrating traditional Chinese medicine with modern medical practices, targeting major disease areas such as cardiovascular, digestive, oncology, and central nervous system disorders [3][8] Company Strategy - Tianshili is transitioning from high-quality products to strong brand recognition, emphasizing a digital marketing system centered on health value [4] - The company employs various promotional strategies, including social media campaigns and educational initiatives, to enhance brand visibility and consumer engagement [5] - Tianshili collaborates with offline strategic partners to create specialized health centers, improving customer service and market penetration [7] Product Performance - In 2024, Tianshili's traditional Chinese medicine segment generated 6.024 billion yuan, with key products like Compound Danshen Dripping Pills and Yangxue Qingnao Granules showing significant sales growth [7] - The company has a robust pipeline for cardiovascular drugs, with ongoing clinical trials for 17 modern Chinese medicine products [10] - Tianshili's innovative products, such as Shao Ma Zhi Jiao Granules and Kun Xin Ning Granules, have received recognition in clinical guidelines, enhancing its market position [10] Innovation and Responsibility - Tianshili emphasizes the integration of modern technology with traditional Chinese medicine to enhance product efficacy and market competitiveness [8] - The company aims to create a three-dimensional innovation system that combines clinical value, digital technology, and patient services [10] - Tianshili's commitment to innovation is reflected in its continuous development of new products and improvement of existing ones, ensuring long-term sustainability [10]

天士力 20250428 摘要 • 天士力融入华润后，正制定十五战略规划，明确自身在华润三九"一体两 翼"模式下的定位和业务发展目标，并积极与华润系各业务单元对接，落 地协同项目，旨在巩固核心业务并拓展新的增长点。 • 2025 年一季度，天士力克服复方丹参滴丸降价压力，实现营收 20.55 亿 元，医药工业主营业务收入 18.42 亿元，同比增长 1.83%；归母净利润 3.14 亿元，同比增长 6.47%，资产负债率维持在 19%的较低水平，整体 经营稳健。 • 复方丹参滴丸虽面临降价压力，但销量和销售收入保持稳定，且新适应症 （如糖尿病视网膜病变）市场潜力巨大，公司正加大推广力度，全年预计 呈现前低后高的增长态势。 • 公司预计 2025 年中药板块保持稳定增长，得益于三大基药品种在基层市 场的推广以及扫码纸巾颗粒和牛黄清心丸等潜力品种的快速增长，其中养 血清脑颗粒在抽动症治疗领域具有独特优势。 • 化学药板块坚持仿创结合，水林佳和地清两大主力产品保持稳定增长，同 时预计 2025 年将有 3 个仿制药新品获批，6 个产品申报，持续提供市场 增量。 Q&A 2025 年公司在中药、化药及生物药三个板块的 ...

涉及总金额6 0 1 . 4 4亿元人民币。 作者 | 私募通 报道 | 决策投资圈 （ID： PEDATAMAX） 清科创业（01945.HK）旗下私募通统计：截至本周五下午，募资、投资、上市和并购共167起事件，涉及总 金额601.44亿人民币。从交易金额来看，本周金额较大事件是：2025年3月27日，华润三九医药股份有限公 司成功受让天士力生物医药产业集团有限公司、天津和悦科技发展合伙企业（有限合伙）、天津康顺科技发 展合伙企业（有限合伙）、天津顺祺科技发展合伙企业（有限合伙）、天津善臻科技发展合伙企业（有限合 伙）等持有的天士力医药集团股份有限公司的28. 0%的股权，作价59.90亿人民币。从交易事件地域分布看， 目前主要分布在广东省、江苏省和浙江省，占比为广东省15.6%，江苏省13.8%，浙江省12 .6%。 更多信息请登录：htt ps://ma x.pe da t a . c n/ 本周新登记股权投资基金管理人共计0家，取消备案登记12家，全年截至目前累计股权投资基金管理人数量 为17家。本周新增备案基金数量为85只，规模总计41 8. 88亿元，本周备案基金募资最多的为南京江宁智慧股 权投 ...